Heat Biologics, Inc.

Leading the Immuno-Oncology Revolution

Heat’s ImPACT Immunotherapy transforms living allogeneic human cancer cells into miniature osmotic pumps that continually secrete cancer antigens to activate a patient's own immune system to destroy the cancer cells.

Learn more about our science

About Us

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.

Learn more about Heat Biologics

View our latest corporate presentation

Recent News

Heat Biologics to Present at PIONEERS 2016, Presented by Joseph Gunnar & Co.

Read More

Heat Biologics Appoints Dr. John Prendergast to Board of Directors

Read More

Events

May 5, 2016

PIONEERS 2016, Presented by Joseph Gunnar & Co.

Learn More

April 16, 2016 - April 20, 2016

AACR Annual Meeting

Learn More

ImPACT Therapy

A First-In-Class Fully Human Cytotoxic T Cell Specific Adjuvant

Heat Biologics’ proprietary ImPACT technology transforms allogenic living cells into miniature osmotic pumps that continually secrete heat shock protein gp96, the most potent mammalian adjuvant ever described, along with its chaperoned antigens.

View our product pipeline